Bal Pharma
Healthcare
BALPHARMA NSE
₹82.15 No trade today
- P/E
- 18.17
Close 4 Nov 2026 ₹82.15 +1.79 +2.23% 1Y
Start ₹80.36
Key Fundamentals
MicrocapPharmaceuticals & BiotechnologyHealthcarePrice-based figures as of · EPS basis: Consolidated · TTM
- ROCE
- 9.69%
- Debt to Equity
- 1.95
- EPS (TTM)
- ₹4.52
- Book Value
- ₹51.65
- Market Cap
- —
- P/E (TTM)
- 18.17
- P/B
- 1.59
- ROE
- 7.87%
- Dividend Yield
- 1.47%
- EBITDA
- ₹33.80 Cr
- 52W High
- ₹124.60
- 52W Low
- ₹60.00
- Volume
- 0
Peer Comparison
Healthcare › Pharmaceuticals
| ₹1,773.40 | 38.81 | ₹4,29,049 Cr | 4.77 | 0.90% | 16.00% | 20.50% | ₹61,631 Cr | ₹10,987 Cr | |
| ₹10,037.50 | 91.10 | ₹2,65,269 Cr | 15.90 | 0.30% | 16.50% | 22.00% | ₹11,230 Cr | ₹2,925 Cr | |
| ₹4,738.50 | 78.61 | ₹1,77,061 Cr | 9.81 | 0.82% | 27.40% | 15.20% | ₹17,400 Cr | ₹2,099 Cr | |
| ₹1,188.10 | 26.44 | ₹1,25,446 Cr | 4.37 | 0.08% | 21.20% | 21.10% | ₹28,592 Cr | ₹4,593 Cr | |
| ₹2,323.80 | 114.81 | ₹1,25,228 Cr | 20.72 | 0.04% | 18.30% | 17.80% | ₹7,270 Cr | ₹1,090 Cr | |
| ₹1,374.00 | 35.59 | ₹1,14,543 Cr | 2.96 | 0.58% | 11.20% | 13.00% | ₹33,228 Cr | ₹3,184 Cr | |
| ₹1,402.00 | 33.59 | ₹1,12,454 Cr | 3.20 | 0.93% | 11.60% | 15.50% | ₹28,324 Cr | ₹3,356 Cr | |
| Bal Pharma (this company) | ₹82.15 | 18.17 | ₹134 Cr | 1.59 | 1.47% | 7.87% | 9.69% | ₹334 Cr | ₹7 Cr |
| Median 8 companies | ₹1,587.70 | 37.20 | ₹1,25,337 Cr | 4.57 | 0.70% | 16.25% | 16.65% | ₹22,862 Cr | ₹3,055 Cr |
Comparable companies in the same industry. Market cap, P/E and P/B use the latest price; other metrics are as reported in filings. A dash means the figure is not published for that company.
Tapetide Score
Data-driven rating, 0–100, as of . How it works →
Overall score
52 Average
Data confidence 100/100
surveillance:ESM1
Category scores
- Quality
- 59
- Good
- Returns, margins, earnings quality 22% weight
- Valuation
- 70
- Strong
- Cheap vs sector & own history 24% weight
- Growth
- 57
- Good
- Sales & profit trajectory 9% weight
- Financial Health
- 21
- Poor
- Solvency, leverage, coverage 9% weight
- Momentum
- 57
- Good
- Trend strength, vol-adjusted 12% weight
- Ownership
- 53
- Average
- FII/DII/promoter flows 24% weight
The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.
Key Insights
Strengths
1- Company has been maintaining a healthy dividend payout of 27.5%
Weaknesses
4- Company has low interest coverage ratio.
- The company has delivered a poor sales growth of 4.46% over past five years.
- Tax rate seems low
- Company has a low return on equity of 9.37% over last 3 years.
Technical Indicators
| Group | Signal | Bearish | Neutral | Bullish |
|---|---|---|---|---|
| Overall | Strong Bearish | 12 | 5 | 2 |
| Oscillators | Neutral | 2 | 5 | 2 |
| Moving Averages | Strong Bearish | 10 | 0 | 0 |
Oscillators
Neutral
Bearish
2
Neutral
5
Bullish
2
Overall
Strong Bearish
Bearish
12
Neutral
5
Bullish
2
Moving Averages
Strong Bearish
Bearish
10
Neutral
0
Bullish
0
Key readings
- RSI (14)
- 37.86
- Neutral
- MACD (12,26,9)
- −4.69
- Bearish
- SMA (50)
- 94.87
- Bearish
- SMA (200)
- 82.75
- Bearish
As of
Growth Rate
From the financial statements below. 10Y, 5Y, 3Y: compound annual growth to Mar 2026; 1Y: fiscal year to Mar 2026 against Mar 2025; TTM: four quarters to Jun 2026 against Jun 2025.
Revenue
| 10Y | +4.65% |
|---|---|
| 5Y | +4.45% |
| 3Y | +0.87% |
| 1Y | +2.97% |
| TTM | +13.52% |
Net profit
| 10Y | +19.62% |
|---|---|
| 5Y | +3.71% |
| 3Y | +25.99% |
| 1Y | −14.29% |
| TTM | +0.84% |
Operating cash flow
| 10Y | Turned positive |
|---|---|
| 5Y | +6.40% |
| 3Y | Turned positive |
| 1Y | +50.00% |
| TTM | — |
TTM: Reported once a year, so there is no trailing-twelve-month figure.
Operating margin· change in pp
| 10Y | +2.68 pp |
|---|---|
| 5Y | +0.30 pp |
| 3Y | +2.04 pp |
| 1Y | +0.36 pp |
| TTM | +0.22 pp |
Revenue by year
| Mar 2017 | ₹229 Cr |
|---|---|
| Mar 2018 | ₹211 Cr |
| Mar 2019 | ₹225 Cr |
| Mar 2020 | ₹171 Cr |
| Mar 2021 | ₹251 Cr |
| Mar 2022 | ₹281 Cr |
| Mar 2023 | ₹304 Cr |
| Mar 2024 | ₹339 Cr |
| Mar 2025 | ₹303 Cr |
| Mar 2026 | ₹312 Cr |
Net profit by year
| Mar 2017 | ₹0.00 Cr |
|---|---|
| Mar 2018 | ₹0.00 Cr |
| Mar 2019 | ₹2.00 Cr |
| Mar 2020 | −₹13.00 Cr |
| Mar 2021 | ₹5.00 Cr |
| Mar 2022 | ₹6.00 Cr |
| Mar 2023 | ₹3.00 Cr |
| Mar 2024 | ₹7.00 Cr |
| Mar 2025 | ₹7.00 Cr |
| Mar 2026 | ₹6.00 Cr |
Quarterly Results
₹ Cr| Particulars | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 70.39 | 92.54 | 81.66 | 94.63 | 74.36 | 73.69 | 73.15 | 81.88 | 65.87 | 74.02 | 87.69 | 84.08 | 88.62 |
| Expenses | 63.95 | 84.84 | 73.87 | 85.03 | 67.89 | 66 | 65.4 | 74.24 | 59.81 | 68.29 | 78.15 | 73.5 | 80.67 |
| Operating Profit | 6.44 | 7.7 | 7.79 | 9.6 | 6.47 | 7.69 | 7.75 | 7.64 | 6.06 | 5.73 | 9.54 | 10.58 | 7.95 |
| OPM % | 9.15% | 8.32% | 9.54% | 10.14% | 8.7% | 10.44% | 10.59% | 9.33% | 9.2% | 7.74% | 10.88% | 12.58% | 8.97% |
| Other Income | 0.16 | 0.14 | 0.1 | 2.45 | 0.82 | −0.2 | 0.51 | 1.08 | 0.72 | 1.12 | 0.33 | −0.24 | 0.44 |
| Interest | 3.64 | 3.82 | 3.66 | 4.14 | 4.24 | 3.65 | 5.01 | 3.95 | 4.05 | 3.86 | 4.85 | 4.06 | 4.47 |
| Depreciation | 2.53 | 2.42 | 2.96 | 2.16 | 2.43 | 2.48 | 2.69 | 2.18 | 2.52 | 2.27 | 3.23 | 3.06 | 2.78 |
| PBT | 0.43 | 1.6 | 1.27 | 5.75 | 0.62 | 1.36 | 0.57 | 2.59 | 0.21 | 0.72 | 1.79 | 3.22 | 1.14 |
| Tax % | 79.07% | 39.38% | 33.07% | 3.65% | 58.06% | 23.53% | 7.14% | −108.88% | 0% | 0% | 0% | −12.11% | 0% |
| Net Profit | 0.09 | 0.97 | 0.85 | 5.53 | 0.26 | 1.04 | 0.52 | 5.41 | 0.21 | 0.72 | 1.79 | 3.6 | 1.14 |
| EPS (₹) | 0.05 | 0.61 | 0.56 | 3.46 | 0.16 | 0.65 | 0.3 | 3.41 | 0.13 | 0.45 | 1.12 | 2.25 | 0.7 |
Profit & Loss
₹ Cr| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 187 | 198 | 229 | 211 | 225 | 171 | 251 | 281 | 304 | 339 | 303 | 312 | 334 |
| Expenses | 170 | 183 | 214 | 194 | 207 | 166 | 226 | 257 | 279 | 308 | 273 | 280 | 301 |
| Operating Profit | 17 | 15 | 15 | 17 | 18 | 5 | 25 | 24 | 25 | 31 | 30 | 32 | 34 |
| OPM % | 9% | 7% | 6% | 8% | 8% | 2.9% | 10% | 9% | 8% | 9% | 10% | 10% | 10% |
| Other Income | 1 | 1 | 3 | 2 | 1 | 2 | 1 | 5 | 1 | 3 | 2 | 2 | 2 |
| Interest | 7 | 6 | 8 | 9 | 13 | 13 | 12 | 11 | 12 | 15 | 17 | 17 | 17 |
| Depreciation | 7 | 7 | 6 | 7 | 6 | 8 | 10 | 9 | 9 | 10 | 10 | 11 | 11 |
| PBT | 5 | 3 | 3 | 3 | 0 | −14 | 4 | 9 | 5 | 9 | 5 | 6 | 7 |
| Tax % | 25% | 90% | 114% | 87% | −1175% | −5% | −15% | 38% | 45% | 18% | −41% | −7% | — |
| Net Profit | 4 | 1 | 0 | 0 | 2 | −13 | 5 | 6 | 3 | 7 | 7 | 6 | 7 |
| EPS (₹) | 2.82 | 1.1 | 1.24 | 1.96 | 2.67 | −8.62 | 3.2 | 3.78 | 1.64 | 4.68 | 4.53 | 3.94 | 4.52 |
| Div. Payout % | 35% | 91% | 81% | 51% | 37% | 0% | 31% | 26% | 61% | 26% | 26% | 30% | — |
Balance Sheet
₹ Cr| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 13 | 13 | 14 | 14 | 14 | 14 | 15 | 15 | 16 | 16 | 16 | 16 |
| Reserves | 42 | 42 | 48 | 51 | 52 | 38 | 39 | 44 | 48 | 56 | 62 | 66 |
| Borrowings | 49 | 89 | 93 | 110 | 124 | 118 | 110 | 104 | 131 | 140 | 150 | 160 |
| Other Liabilities | 59 | 67 | 78 | 86 | 71 | 68 | 76 | 98 | 116 | 108 | 108 | 134 |
| Total Liabilities | 164 | 211 | 233 | 260 | 261 | 238 | 240 | 261 | 311 | 320 | 336 | 376 |
| Fixed Assets | 52 | 56 | 60 | 71 | 70 | 71 | 69 | 67 | 76 | 80 | 87 | 94 |
| CWIP | 1 | 4 | 2 | 0 | 4 | 3 | 0 | 2 | 0 | 0 | 3 | 7 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 7 | 2 | 2 |
| Other Assets | 111 | 151 | 172 | 188 | 187 | 164 | 172 | 192 | 235 | 233 | 244 | 272 |
| Total Assets | 164 | 211 | 233 | 260 | 261 | 238 | 240 | 261 | 311 | 320 | 336 | 376 |
Cash Flow
₹ Cr| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating | 15 | −19 | 6 | 1 | 8 | 23 | 22 | 27 | −2 | 23 | 20 | 30 |
| Investing | −5 | −14 | −8 | −4 | −8 | −5 | −6 | −9 | −22 | −19 | −15 | −21 |
| Financing | −7 | 32 | −6 | 4 | 0 | −20 | −17 | −17 | 24 | −1 | −8 | −10 |
| Net Cash Flow | 2 | −1 | −8 | 1 | 0 | −2 | 0 | 0 | 0 | 3 | −2 | 0 |
| Free Cash Flow | 9 | −34 | −2 | −3 | −1 | 18 | 19 | 18 | −16 | 12 | 2 | 8 |
| CFO/OP | 93 | −125 | 52 | 11 | 57 | 465 | 91 | 117 | −4 | 88 | 75 | 95 |
Ratios
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 88 | 105 | 99 | 111 | 105 | 106 | 98 | 98 | 113 | 107 | 111 | 110 |
| Inventory Days | 132 | 145 | 172 | 240 | 217 | 292 | 146 | 162 | 207 | 167 | 238 | 269 |
| Days Payable | 142 | 163 | 171 | 182 | 147 | 167 | 114 | 143 | 167 | 147 | 189 | 206 |
| Cash Conversion Cycle | 78 | 87 | 100 | 168 | 175 | 231 | 130 | 117 | 153 | 127 | 161 | 173 |
| Working Capital Days | 14 | 50 | 26 | 45 | 25 | −11 | 11 | 18 | 13 | 12 | 6 | 7 |
| ROCE % | 11% | 7% | 8% | 8% | 7% | 0% | 10% | 12% | 10% | 12% | 10% | 10% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Bal Pharma insights
75 extracted metrics across FY12–FY27.
Documents
- 11 Feb 2026
- 28 Aug 2026
- 9 Jun 2025
- 30 Dec 2024
- 22 May 2024
- 21 Apr 2023
- General announcements 7 Oct 2026
Frequently Asked Questions about Bal Pharma
What does Bal Pharma Ltd do?
Incorporated in 1987, Bal Pharma Ltd does manufacturing and selling of pharmaceutical products and related services
Where is Bal Pharma Ltd (BALPHARMA) listed?
Bal Pharma Ltd trades as BALPHARMA on the NSE and under code 524824 on the BSE.
Which sector does Bal Pharma Ltd belong to?
Bal Pharma Ltd is classified under the Healthcare sector, in the Pharmaceuticals industry.
What is the PE ratio of Bal Pharma Ltd?
Bal Pharma Ltd trades at a PE ratio of 18.17 as of 4 Nov 2026, on earnings per share of ₹4.52, against a book value of ₹51.65 per share.
What is the 52-week high and low of Bal Pharma Ltd?
Over the last 52 weeks Bal Pharma Ltd has traded between ₹60 and ₹124.6 as of 4 Nov 2026.
Does Bal Pharma Ltd pay dividends?
Bal Pharma Ltd has a dividend yield of 1.47%.
What is the Return on Equity (ROE) of Bal Pharma Ltd?
Bal Pharma Ltd reported a return on equity of 7.87%. Its debt-to-equity ratio is 1.95.
Company Information
Incorporated in 1987, Bal Pharma Ltd does manufacturing and selling of pharmaceutical products and related services
Website balpharma.com
CEO Mr. Shailesh Dheerajmal Siroya
Employees 986
Listed 8 May 2006
Face Value ₹10
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/BALPHARMA.md for Bal Pharma Ltd: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.
Append .md to any Tapetide URL for
the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For
live, structured queries instead of documents, use our Indian stock market MCP server.